0.014124
0.008155
0.000000
0.000000
0.016309
0.000000
0.000000
0.000000
0.004789
0.00000
0.00000
0.00000
Herman, M.D.
Lehtio, L.
Arrowsmith, C.H.
Berglund, H.
Busam, R.D.
Collins, R.
Dahlgren, L.G.
Edwards, A.M.
Flodin, S.
Flores, A.
Graslund, S.
Hammarstrom, M.
Johansson, I.
Kallas, A.
Karlberg, T.
Kotenyova, T.
Moche, M.
Nilsson, M.E.
Nyman, T.
Persson, C.
Sagemark, J.
Svensson, L.
Thorsell, A.G.
Tresaugues, L.
van den Berg, S.
Weigelt, J.
Welin, M.
Nordlund, P.
Structural Genomics Consortium (SGC)
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
18
90.00
90.00
120.00
70.800
70.800
208.800
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
H2 O
18.015
WATER
non-polymer
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
O4 S -2
96.063
SULFATE ION
non-polymer
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
NE
FEBS Lett.
FEBLAL
0165
0014-5793
582
3590
10.1016/J.FEBSLET.2008.09.028
18812174
Completing the Family Portrait of the Anti- Apoptotic Bcl-2 Proteins: Crystal Structure of Human Bfl-1 in Complex with Bim.
2008
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
100
1
MIRRORS
CCD
2007-09-27
ADSC CCD
DIAMOND (111), GE(220)
SINGLE WAVELENGTH
M
x-ray
1
0.934000
1.0
ID14-1
ESRF
0.934000
SYNCHROTRON
ESRF BEAMLINE ID14-1
17246.617
BCL-2-RELATED PROTEIN A1
RESIDUES 1-149
1
man
polymer
3117.497
BCL-2-LIKE PROTEIN 11
RESIDUES 141-165
1
man
polymer
96.063
SULFATE ION
1
syn
non-polymer
18.015
water
38
nat
water
PROTEIN BFL-1, HEMOPOIETIC-SPECIFIC EARLY RESPONSE PROTEIN, PROTEIN GRS, BCL-2A1, A1
BCL2-INTERACTING MEDIATOR OF CELL DEATH
no
no
SMTDCEFGYIYRLAQDYLQCVLQIPQPGSGPSKTSRVLQNVAFSVQKEVEKNLKSCLDNVNVVSVDTARTLFNQVMEKEF
EDGIINWGRIVTIFAFEGILIKKLLRQQIAPDVDTYKEISYFVAEFIMNNTGEWIRQNGGWENGFVKKFE
SMTDCEFGYIYRLAQDYLQCVLQIPQPGSGPSKTSRVLQNVAFSVQKEVEKNLKSCLDNVNVVSVDTARTLFNQVMEKEF
EDGIINWGRIVTIFAFEGILIKKLLRQQIAPDVDTYKEISYFVAEFIMNNTGEWIRQNGGWENGFVKKFE
A
polypeptide(L)
no
no
DMRPEIWIAQELRRIGDEFNAYYAR
DMRPEIWIAQELRRIGDEFNAYYAR
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
HUMAN
sample
9606
HOMO SAPIENS
469008
ESCHERICHIA COLI
BL21(DE3) R3 PRARE
PNIC-BSA4
HUMAN
sample
9606
HOMO SAPIENS
469008
ESCHERICHIA COLI
BL21(DE3) R3 PRARE
PNIC-BSA4
2
2.48
50.4
NONE
VAPOR DIFFUSION, HANGING DROP
5.8
0.1M BIS, TRIS PH 5.8, 2M AMSO4
293
exptl_crystal_grow
pdbx_database_status
reflns
repository
Initial release
Advisory
Refinement description
Version format compliance
Data collection
Experimental preparation
Other
1
0
2008-02-05
1
1
2011-07-13
1
2
2019-09-25
_exptl_crystal_grow.method
_exptl_crystal_grow.temp
_pdbx_database_status.status_code_sf
_reflns.pdbx_Rmerge_I_obs
HUMAN BIR2 DOMAIN OF BACULOVIRAL INHIBITOR OF APOPTOSIS REPEAT-CONTAINING 1 (BIRC1
CRYSTAL STRUCTURE OF A BHRF-1 : BIM BH3 COMPLEX
PDBE
Y
PDBE
2008-01-23
REL
REL
SO4
SULFATE ION
HOH
water
SO4
1150
3
SO4
SO4
1150
A
HOH
2001
4
HOH
HOH
2001
A
HOH
2002
4
HOH
HOH
2002
A
HOH
2003
4
HOH
HOH
2003
A
HOH
2004
4
HOH
HOH
2004
A
HOH
2005
4
HOH
HOH
2005
A
HOH
2006
4
HOH
HOH
2006
A
HOH
2007
4
HOH
HOH
2007
A
HOH
2008
4
HOH
HOH
2008
A
HOH
2009
4
HOH
HOH
2009
A
HOH
2010
4
HOH
HOH
2010
A
HOH
2011
4
HOH
HOH
2011
A
HOH
2012
4
HOH
HOH
2012
A
HOH
2013
4
HOH
HOH
2013
A
HOH
2014
4
HOH
HOH
2014
A
HOH
2015
4
HOH
HOH
2015
A
HOH
2016
4
HOH
HOH
2016
A
HOH
2017
4
HOH
HOH
2017
A
HOH
2018
4
HOH
HOH
2018
A
HOH
2019
4
HOH
HOH
2019
A
HOH
2020
4
HOH
HOH
2020
A
HOH
2021
4
HOH
HOH
2021
A
HOH
2022
4
HOH
HOH
2022
A
HOH
2023
4
HOH
HOH
2023
A
HOH
2024
4
HOH
HOH
2024
A
HOH
2025
4
HOH
HOH
2025
A
HOH
2026
4
HOH
HOH
2026
A
HOH
2027
4
HOH
HOH
2027
A
HOH
2028
4
HOH
HOH
2028
A
HOH
2029
4
HOH
HOH
2029
A
HOH
2030
4
HOH
HOH
2030
A
HOH
2031
4
HOH
HOH
2031
A
HOH
2032
4
HOH
HOH
2032
A
HOH
2001
4
HOH
HOH
2001
B
HOH
2002
4
HOH
HOH
2002
B
HOH
2003
4
HOH
HOH
2003
B
HOH
2004
4
HOH
HOH
2004
B
HOH
2005
4
HOH
HOH
2005
B
HOH
2006
4
HOH
HOH
2006
B
SER
0
n
1
SER
0
A
MET
1
n
2
MET
1
A
THR
2
n
3
THR
2
A
ASP
3
n
4
ASP
3
A
CYS
4
n
5
CYS
4
A
GLU
5
n
6
GLU
5
A
PHE
6
n
7
PHE
6
A
GLY
7
n
8
GLY
7
A
TYR
8
n
9
TYR
8
A
ILE
9
n
10
ILE
9
A
TYR
10
n
11
TYR
10
A
ARG
11
n
12
ARG
11
A
LEU
12
n
13
LEU
12
A
ALA
13
n
14
ALA
13
A
GLN
14
n
15
GLN
14
A
ASP
15
n
16
ASP
15
A
TYR
16
n
17
TYR
16
A
LEU
17
n
18
LEU
17
A
GLN
18
n
19
GLN
18
A
CYS
19
n
20
CYS
19
A
VAL
20
n
21
VAL
20
A
LEU
21
n
22
LEU
21
A
GLN
22
n
23
GLN
22
A
ILE
23
n
24
ILE
23
A
PRO
24
n
25
PRO
24
A
n
26
25
A
n
27
26
A
n
28
27
A
n
29
28
A
n
30
29
A
n
31
30
A
SER
31
n
32
SER
31
A
LYS
32
n
33
LYS
32
A
THR
33
n
34
THR
33
A
SER
34
n
35
SER
34
A
ARG
35
n
36
ARG
35
A
VAL
36
n
37
VAL
36
A
LEU
37
n
38
LEU
37
A
GLN
38
n
39
GLN
38
A
ASN
39
n
40
ASN
39
A
VAL
40
n
41
VAL
40
A
ALA
41
n
42
ALA
41
A
PHE
42
n
43
PHE
42
A
SER
43
n
44
SER
43
A
VAL
44
n
45
VAL
44
A
GLN
45
n
46
GLN
45
A
LYS
46
n
47
LYS
46
A
GLU
47
n
48
GLU
47
A
VAL
48
n
49
VAL
48
A
GLU
49
n
50
GLU
49
A
LYS
50
n
51
LYS
50
A
ASN
51
n
52
ASN
51
A
LEU
52
n
53
LEU
52
A
LYS
53
n
54
LYS
53
A
SER
54
n
55
SER
54
A
CYS
55
n
56
CYS
55
A
LEU
56
n
57
LEU
56
A
ASP
57
n
58
ASP
57
A
ASN
58
n
59
ASN
58
A
VAL
59
n
60
VAL
59
A
ASN
60
n
61
ASN
60
A
VAL
61
n
62
VAL
61
A
VAL
62
n
63
VAL
62
A
SER
63
n
64
SER
63
A
VAL
64
n
65
VAL
64
A
ASP
65
n
66
ASP
65
A
THR
66
n
67
THR
66
A
ALA
67
n
68
ALA
67
A
ARG
68
n
69
ARG
68
A
THR
69
n
70
THR
69
A
LEU
70
n
71
LEU
70
A
PHE
71
n
72
PHE
71
A
ASN
72
n
73
ASN
72
A
GLN
73
n
74
GLN
73
A
VAL
74
n
75
VAL
74
A
MET
75
n
76
MET
75
A
GLU
76
n
77
GLU
76
A
LYS
77
n
78
LYS
77
A
GLU
78
n
79
GLU
78
A
PHE
79
n
80
PHE
79
A
GLU
80
n
81
GLU
80
A
ASP
81
n
82
ASP
81
A
GLY
82
n
83
GLY
82
A
ILE
83
n
84
ILE
83
A
ILE
84
n
85
ILE
84
A
ASN
85
n
86
ASN
85
A
TRP
86
n
87
TRP
86
A
GLY
87
n
88
GLY
87
A
ARG
88
n
89
ARG
88
A
ILE
89
n
90
ILE
89
A
VAL
90
n
91
VAL
90
A
THR
91
n
92
THR
91
A
ILE
92
n
93
ILE
92
A
PHE
93
n
94
PHE
93
A
ALA
94
n
95
ALA
94
A
PHE
95
n
96
PHE
95
A
GLU
96
n
97
GLU
96
A
GLY
97
n
98
GLY
97
A
ILE
98
n
99
ILE
98
A
LEU
99
n
100
LEU
99
A
ILE
100
n
101
ILE
100
A
LYS
101
n
102
LYS
101
A
LYS
102
n
103
LYS
102
A
LEU
103
n
104
LEU
103
A
LEU
104
n
105
LEU
104
A
ARG
105
n
106
ARG
105
A
GLN
106
n
107
GLN
106
A
GLN
107
n
108
GLN
107
A
ILE
108
n
109
ILE
108
A
ALA
109
n
110
ALA
109
A
PRO
110
n
111
PRO
110
A
ASP
111
n
112
ASP
111
A
VAL
112
n
113
VAL
112
A
ASP
113
n
114
ASP
113
A
THR
114
n
115
THR
114
A
TYR
115
n
116
TYR
115
A
LYS
116
n
117
LYS
116
A
GLU
117
n
118
GLU
117
A
ILE
118
n
119
ILE
118
A
SER
119
n
120
SER
119
A
TYR
120
n
121
TYR
120
A
PHE
121
n
122
PHE
121
A
VAL
122
n
123
VAL
122
A
ALA
123
n
124
ALA
123
A
GLU
124
n
125
GLU
124
A
PHE
125
n
126
PHE
125
A
ILE
126
n
127
ILE
126
A
MET
127
n
128
MET
127
A
ASN
128
n
129
ASN
128
A
ASN
129
n
130
ASN
129
A
THR
130
n
131
THR
130
A
GLY
131
n
132
GLY
131
A
GLU
132
n
133
GLU
132
A
TRP
133
n
134
TRP
133
A
ILE
134
n
135
ILE
134
A
ARG
135
n
136
ARG
135
A
GLN
136
n
137
GLN
136
A
ASN
137
n
138
ASN
137
A
GLY
138
n
139
GLY
138
A
GLY
139
n
140
GLY
139
A
TRP
140
n
141
TRP
140
A
GLU
141
n
142
GLU
141
A
ASN
142
n
143
ASN
142
A
GLY
143
n
144
GLY
143
A
PHE
144
n
145
PHE
144
A
VAL
145
n
146
VAL
145
A
LYS
146
n
147
LYS
146
A
LYS
147
n
148
LYS
147
A
PHE
148
n
149
PHE
148
A
GLU
149
n
150
GLU
149
A
ASP
141
n
1
ASP
141
B
MET
142
n
2
MET
142
B
ARG
143
n
3
ARG
143
B
PRO
144
n
4
PRO
144
B
GLU
145
n
5
GLU
145
B
ILE
146
n
6
ILE
146
B
TRP
147
n
7
TRP
147
B
ILE
148
n
8
ILE
148
B
ALA
149
n
9
ALA
149
B
GLN
150
n
10
GLN
150
B
GLU
151
n
11
GLU
151
B
LEU
152
n
12
LEU
152
B
ARG
153
n
13
ARG
153
B
ARG
154
n
14
ARG
154
B
ILE
155
n
15
ILE
155
B
GLY
156
n
16
GLY
156
B
ASP
157
n
17
ASP
157
B
GLU
158
n
18
GLU
158
B
PHE
159
n
19
PHE
159
B
ASN
160
n
20
ASN
160
B
ALA
161
n
21
ALA
161
B
TYR
162
n
22
TYR
162
B
TYR
163
n
23
TYR
163
B
ALA
164
n
24
ALA
164
B
ARG
165
n
25
ARG
165
B
4.2234
0.0842
0.9229
2.9115
-0.0071
1.3450
0.2037
0.1462
-0.1986
-0.3558
-0.1641
0.0423
-0.0705
-0.0767
-0.0396
-0.0312
0.0533
0.0299
-0.1180
0.0149
-0.1535
refined
-5.5900
20.2230
52.3430
X-RAY DIFFRACTION
A
0
A
149
X-RAY DIFFRACTION
1
B
141
B
165
X-RAY DIFFRACTION
1
author_and_software_defined_assembly
PQS
2
dimeric
2770
-22.6
10260
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
HOH
2019
D
HOH
1
A
CG
MET
1
A
CG
MET
2
1
Y
1
A
SD
MET
1
A
SD
MET
2
1
Y
1
A
CE
MET
1
A
CE
MET
2
1
Y
1
A
GLN
25
A
GLN
26
1
Y
1
A
PRO
26
A
PRO
27
1
Y
1
A
GLY
27
A
GLY
28
1
Y
1
A
SER
28
A
SER
29
1
Y
1
A
GLY
29
A
GLY
30
1
Y
1
A
PRO
30
A
PRO
31
1
Y
1
A
THR
114
-62.07
5.89
37.38
-0.24000
-0.12000
0.00000
-0.24000
0.00000
0.36000
0.947
0.902
HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. RESIDUES 25-30 ARE DISORDERED, FIRST SER IS FROM VECTOR.
0.250
0.194
0.196
2.20
20.00
503
10075
4.800
99.9
10.977
0.137
RANDOM
LIKELY RESIDUAL
1
THROUGHOUT
MAD
0.250
0.211
0.80
0.80
1.20
NONE
MAXIMUM LIKELIHOOD
MASK
2.20
20.00
38
1436
5
0
1393
0.014
0.022
1423
1.401
1.939
1920
5.748
5.000
166
35.804
24.545
77
15.772
15.000
254
19.945
15.000
10
0.096
0.200
207
0.006
0.020
1083
0.209
0.200
715
0.308
0.200
1012
0.131
0.200
52
0.178
0.200
44
0.144
0.200
9
0.852
1.500
872
1.387
2.000
1353
2.157
3.000
652
3.307
4.500
567
0.2470
0.1930
2.26
40
708
20
2.20
20.00
2VM6
10576
2.0
0.066
1
30.27
11.7
99.7
0.52
2.20
2.30
4.75
1
8.9
100.0
refinement
REFMAC
5.3.0040
data reduction
XDS
data scaling
XSCALE
phasing
SOLVE
BCL-2-RELATED PROTEIN A1, BCL-2-LIKE PROTEIN 11
Human Bcl2-A1 in complex with Bim-BH3 peptide
1
N
N
2
N
N
3
N
N
4
N
N
4
N
N
A
SER
0
A
SER
1
HELX_P
A
LEU
21
A
LEU
22
1
1
22
A
SER
31
A
SER
32
HELX_P
A
LEU
52
A
LEU
53
1
2
22
A
LEU
52
A
LEU
53
HELX_P
A
ASP
57
A
ASP
58
1
3
6
A
SER
63
A
SER
64
HELX_P
A
GLU
80
A
GLU
81
1
4
18
A
ASN
85
A
ASN
86
HELX_P
A
GLN
107
A
GLN
108
1
5
23
A
VAL
112
A
VAL
113
HELX_P
A
THR
114
A
THR
115
5
6
3
A
TYR
115
A
TYR
116
HELX_P
A
ASN
137
A
ASN
138
1
7
23
A
GLY
138
A
GLY
139
HELX_P
A
GLY
143
A
GLY
144
1
8
6
A
GLY
143
A
GLY
144
HELX_P
A
GLU
149
A
GLU
150
1
9
7
B
ARG
143
B
ARG
3
HELX_P
B
TYR
163
B
TYR
23
1
10
21
IMMUNE SYSTEM
B-CELL LYMPHOMA2, ANTIAPOPTOTIC, IMMUNE SYSTEM, BIM, BFL-1, BCL2A1, BCL-2A1, MEMBRANE, APOPTOSIS
2VM6
PDB
1
2VM6
B2LA1_HUMAN
UNP
1
Q16548
BIM_HUMAN
UNP
2
O43521
0
0
2VM6
0
0
2VM6
A
1
1
1
1
149
2VM6
1
149
Q16548
A
2
2
150
141
165
2VM6
141
165
O43521
B
3
1
25
BINDING SITE FOR RESIDUE SO4 A1150
Software
3
A
LYS
147
A
LYS
148
3
1_555
B
ALA
164
B
ALA
24
3
1_555
B
ARG
165
B
ARG
25
3
1_555
155
H 3 2